Short Communication

iMedPub Journals
http://www.imedpub.com/

Chronic Obstructive Pulmonary Disease: Open Access
ISSN 2572-5548

2025
Vol.10 No.01: 05

Systemic Inflammation in COPD Progression and Comorbidities

Owada Dawkins*

Department of Pulmonary Biology and Regenerative Medicine, University of Zurich, Zurich, Switzerland

***Corresponding author:** Owada Dawkins, Department of Pulmonary Biology and Regenerative Medicine, University of Zurich, Zurich, Switzerland; E-mail: dawkinsowada@ies.ch

Rec date: January 06, 2025; **Acc date:** January 08, 2025; **Pub date:** January 31, 2025

Citation: Dawkins O. (2025) Systemic Inflammation in COPD Progression and Comorbidities. Chron Obstruct Pulmon Dis 10.01: 05.

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by persistent airflow limitation, structural changes in the lung parenchyma, and progressive respiratory decline. Traditionally considered a localized disease of the lungs, COPD is now increasingly recognized as a systemic condition with widespread effects on multiple organs. Central to this expanded view is the concept of systemic inflammation, a chronic, low-grade inflammatory state that extends beyond the pulmonary compartment and contributes not only to COPD progression but also to the development of comorbid conditions such as cardiovascular disease, metabolic syndrome, diabetes, osteoporosis, skeletal muscle wasting, and even neurocognitive impairment. The persistence of systemic inflammation despite smoking cessation and standard pharmacological therapies highlights its independent role in the disease trajectory. This evolving understanding of COPD underscores the need to address systemic inflammation as both a driver of disease progression and a therapeutic target for improving outcomes in affected patients [1].

Description

The origins of systemic inflammation in COPD can be traced to several interrelated mechanisms within the lung microenvironment. Cigarette smoke exposure, environmental pollutants, and recurrent infections initiate persistent inflammatory signaling in the airways and alveoli. Epithelial cells, alveolar macrophages, and neutrophils release pro-inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), C-reactive protein and chemokines, which not only perpetuate local tissue injury but also spill into systemic circulation. However, emerging evidence suggests a bidirectional interplay in which systemic inflammatory processes can feed back into the lungs, amplifying disease severity. Circulating immune cells, primed by systemic inflammation, infiltrate pulmonary tissues and exacerbate oxidative stress, protease-antiprotease imbalance, and structural remodeling, thereby accelerating lung function decline [2].

Systemic inflammation plays a central role in cardiovascular comorbidities, which are highly prevalent in COPD patients. Atherosclerosis, ischemic heart disease, arrhythmias, and heart failure are strongly associated with elevated inflammatory mediators such as CRP, IL-6, and fibrinogen. These biomarkers, frequently elevated in COPD, promote endothelial dysfunction, vascular remodeling, and plaque instability. Studies have demonstrated that COPD patients with high systemic inflammatory burden exhibit greater arterial stiffness and coronary artery calcification, both of which are predictors of adverse cardiovascular outcomes. Moreover, hypoxia in advanced COPD induces polycythemia and increases blood viscosity, compounding vascular injury. Exacerbations of COPD, often triggered by infections, produce acute inflammatory surges that can precipitate myocardial infarction or stroke, illustrating the dynamic link between pulmonary inflammation and systemic cardiovascular events. The recognition of this inflammatory overlap has important clinical implications, as anti-inflammatory therapies may simultaneously reduce respiratory and cardiovascular morbidity [3,4].

Metabolic disorders, including diabetes mellitus and metabolic syndrome, also share mechanistic connections with systemic inflammation in COPD. Chronic elevation of cytokines such as TNF-α and IL-6 induces insulin resistance by interfering with insulin receptor signaling in adipose tissue, skeletal muscle, and the liver. Additionally, systemic inflammation promotes lipolysis, abnormal fat distribution, and dyslipidemia, all of which are hallmarks of metabolic syndrome. COPD patients often display sarcopenic obesity, characterized by a paradoxical combination of skeletal muscle wasting and central fat accumulation, driven in part by systemic inflammation. Muscle catabolism is mediated by pro-inflammatory cytokines that activate proteolytic pathways such as the ubiquitin-proteasome system, leading to progressive functional decline. Furthermore, systemic inflammation contributes to mitochondrial dysfunction in skeletal muscle, impairing energy metabolism and exercise tolerance, thereby perpetuating the cycle of physical inactivity, weight gain, and worsening COPD outcomes. Neurocognitive and psychological comorbidities also have roots in systemic inflammation. Cognitive decline, depression, and anxiety are highly prevalent in COPD patients and contribute significantly to disease burden. Another dimension of systemic inflammation in COPD is its impact on disease exacerbations and mortality risk [5].

Conclusion

Systemic inflammation is increasingly recognized as a central feature of COPD that extends far beyond the lungs, shaping disease progression, comorbidity development, and patient outcomes. It arises from a combination of inflammatory spillover from the lungs, oxidative stress, immune dysregulation, and metabolic imbalance, and it exerts deleterious effects on cardiovascular health, metabolism, bone integrity, skeletal muscle function, and neurocognitive performance. The systemic inflammation phenotype of COPD represents a high-risk subgroup that requires tailored management strategies. Addressing systemic inflammation offers the potential not only to slow COPD progression but also to reduce the burden of comorbidities, thereby improving survival and quality of life. Future research must refine biomarker-based patient stratification, elucidate the molecular pathways linking systemic inflammation to comorbidities, and develop targeted therapies capable of modulating systemic inflammation safely and effectively. By embracing this holistic perspective, the management of COPD can move toward a truly integrated approach that addresses both pulmonary and systemic disease components, ultimately transforming the trajectory of this devastating condition.

Acknowledgment

None.

Conflict of Interest

None.

REFERENCES

1. Fernandez-Gonzalez A, Mukhia A, Nadkarni J, Willis GR, Reis M, et al. (2024). Immunoregulatory macrophages modify local pulmonary immunity and ameliorate hypoxic pulmonary hypertension. Arterioscler Thromb Vasc Biol 44: e288-e303.

2. Jankov RP, Kantores C, Pan J, Belik J (2008). Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Lung Cell Mol Physiol 294: L233-L245.

3. Zheng X, Zhao J, Jia X, Pan J, Xu S, et al. (2025). Fucoxanthin ameliorates vascular remodeling *via* attenuating oxidative stress in hypoxic pulmonary hypertension rats. J Nutr Biochem 110002.

4. Yu YR A, Malakhau Y, Yu CHA, Phelan SLJ, Cumming RI, et al. (2020). Nonclassical monocytes sense hypoxia, regulate pulmonary vascular remodeling and promote pulmonary hypertension. J Immunol 204: 1474-1485.

5. Kumar R, Mickael C, Kassa B, Gebreab L, Robinson JC, et al. (2017). TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma-and hypoxia-induced pulmonary hypertension. Nat Commun 8: 15494.